Associate Professor Michael Patrick Hay
BSc (Hons), PhD
Michael Hay obtained his BSc (Hons) and PhD in Chemistry from The University of Canterbury, New Zealand. After postdoctoral positions at Imperial College, London, and the University of Auckland, Michael was appointed as a Research Fellow in the Auckland Cancer Society Research Centre in 1991. He was appointed as an Associate Professor in 2011 and leads a group investigating tumour selective drug delivery targeting the tumour microenvironment. Michael was appointed Director of the ACSRC in 2020.
Research | Current
Michael is interested in developing novel therapeutics that target the tumour microenvironment through bioreductive mechanisms and/or selective target inhibition. Current research interests include:
- Discovery of new hypoxia-activated prodrugs
- Development of nitroimidazole-based radiosensitisers
- Development of novel agents targeting DNA damage response pathways.
- Development of hypoxia-selective cytotoxins and radiation response modifiers based on the 1,2,4-benzotriazine dioxide core.
- Design and synthesis of drugs that target hypoxia-inducible factor (HIF-1alpha).
Fellow of the New Zealand Institute of Chemistry
Member of the Medical Committee Auckland Medical Research Foundation
Member of the Biotechnology and Biomedical Sciences Committee, Australian Institute of Nuclear Sciences and Engineering
Selected publications and creative works (Research Outputs)
- Hendrikse, E. R., Liew, L. P., Bower, R. L., Bonnet, M., Jamaluddin, M. A., Prodan, N., ... Smith, D. M. (2020). Identification of Small-Molecule Positive Modulators of Calcitonin-like Receptor-Based Receptors. ACS pharmacology & translational science, 3 (2), 305-320. 10.1021/acsptsci.9b00108
Other University of Auckland co-authors: Aqfan Jamaluddin, Keith Richards, Christopher Walker
- Lee, T. W., Wong, W. W., Dickson, B. D., Lipert, B., Cheng, G. J., Hunter, F. W., ... Wilson, W. R. (2019). Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia. International journal of radiation biology, 95 (12), 1597-1612. 10.1080/09553002.2019.1664787
Other University of Auckland co-authors: Francis Hunter, Benjamin Dickson, Barbara Lipert, Way Wong
- Wong, W. W., Jackson, R. K., Liew, L. P., Dickson, B. D., Cheng, G. J., Lipert, B., ... Hay, M. P. (2019). Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361. Biochemical pharmacology, 16910.1016/j.bcp.2019.113641
Other University of Auckland co-authors: Barbara Lipert, Way Wong, Benjamin Dickson, Yongchuan Gu, Francis Hunter, Lydia Liew
- Jackson, R. K., Liew, L. P., & Hay, M. P. (2019). Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs. Clinical oncology (Royal College of Radiologists (Great Britain)), 31 (5), 290-302. 10.1016/j.clon.2019.02.004
Other University of Auckland co-authors: Lydia Liew
- Dickson, B. D., Wong, W. W., Wilson, W. R., & Hay, M. P. (2019). Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors. Molecules (Basel, Switzerland), 24 (8).10.3390/molecules24081559
Other University of Auckland co-authors: Benjamin Dickson, Way Wong
- Liew, L. P., Singleton, D. C., Wong, W. W., Cheng, G. J., Jamieson, S. M. F., & Hay, M. P. (2019). Hypoxia‐Activated Prodrugs of PERK Inhibitors. Chemistry - An Asian Journal, 14 (8), 1238-1248. 10.1002/asia.201801826
Other University of Auckland co-authors: Lydia Liew, Dean Singleton, Way Wong, Stephen Jamieson
- Lu, M., Flanagan, J. U., Langley, R. J., Hay, M. P., & Perry, J. K. (2019). Targeting growth hormone function: strategies and therapeutic applications. Signal transduction and targeted therapy, 410.1038/s41392-019-0036-y
Other University of Auckland co-authors: Ries Langley, Jo Perry, Jack Flanagan
- Chernikova, S. B., Nguyen, R. B., Truong, J. T., Mello, S. S., Stafford, J. H., Hay, M. P., ... Henry, S. (2018). Dynamin impacts homology-directed repair and breast cancer response to chemotherapy. The Journal of clinical investigation, 128 (12), 5307-5321. 10.1172/jci87191